Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III RO7790121 treat-through study in moderately to severely active ulcerative colitis
ChiCTR2400093667Phase 3Recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing RO7790121 with Placebo (2 arms). Primary endpoint: Clinical remission. Started Dec 2024; status: recruiting.
02
Drugs
afimkibart
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on ChiCTR2400093667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093667.